Valuation Gedeon Richter LUXEMBOURG S.E.

Stocks

End-of-day quote LUXEMBOURG S.E. 11/11/2026			5-day change	1st Jan Change
39.40 ^USD	-1.01%		-1.50%	+30.46%

11-10	Gedeon Richter PLC Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
10-14	Gedeon Richter Plc. Receives Fda Submission Acceptance of New Drug Application for Fylrevy® in the U.S	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	1,619,625	1,542,290	1,627,029	1,893,161	1,799,226	2,398,436	-	-
Change	-	-4.77%	5.49%	16.36%	-4.96%	33.3%	-	-
Enterprise Value (EV) ¹	1,559,769	1,395,557	1,546,536	1,782,343	1,588,618	2,135,960	1,988,424	1,861,456
Change	-	-10.53%	10.82%	15.25%	-10.87%	34.45%	-6.91%	-6.39%
P/E	11.6x	9.94x	10.2x	7.96x	7.76x	9.67x	8.27x	7.66x
PBR	1.78x	1.47x	1.44x	1.49x	1.31x	1.6x	1.44x	1.31x
PEG	-	0.9x	3.41x	0.2x	-2.82x	1.39x	0.5x	0.95x
Capitalization / Revenue	2.57x	1.92x	2.02x	2.21x	1.94x	2.38x	2.35x	2.19x
EV / Revenue	2.47x	1.74x	1.92x	2.08x	1.71x	2.12x	1.95x	1.7x
EV / EBITDA	8.86x	7.1x	6.43x	5.74x	4.5x	5.71x	5.02x	4.38x
EV / EBIT	11.5x	9.09x	8.15x	6.82x	5.42x	6.89x	5.97x	5.18x
EV / FCF	-460x	12.3x	17.9x	8.26x	7.56x	9.46x	8.67x	7.52x
FCF Yield	-0.22%	8.12%	5.6%	12.1%	13.2%	10.6%	11.5%	13.3%
Dividend per Share ²	225	390	-	-	-	603.6	677	738.7
Rate of return	2.58%	4.7%	-	-	-	4.59%	5.15%	5.62%
EPS ²	751	835	860	1,307	1,271	1,359	1,589	1,718
Distribution rate	30%	46.7%	-	-	-	44.4%	42.6%	43%
Net sales ¹	630,595	802,755	805,158	857,545	928,962	1,008,000	1,020,834	1,093,689
EBITDA ¹	176,123	196,480	240,625	310,678	353,314	374,000	396,366	425,015
EBIT ¹	135,832	153,555	189,817	261,157	292,851	310,000	332,887	359,032
Net income ¹	139,626	155,581	158,850	239,244	232,335	269,000	290,549	314,929
Net Debt ¹	-59,856	-146,733	-80,493	-110,818	-210,608	-262,476	-410,012	-536,980
Reference price ²	8,725.00	8,300.00	8,750.00	10,400.00	9,865.00	13,150.00	13,150.00	13,150.00
Nbr of stocks (in thousands)	185,630	185,818	185,946	182,035	182,385	182,391	-	-
Announcement Date	02/03/22	28/02/23	29/02/24	07/04/25	27/02/26	-	-	-

¹HUF in Million²HUF

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	41.91x	14.16x	30.08x	0.48%	1,276B
JOHNSON & JOHNSON	41.09x	6.89x	19.39x	1.9%	676B
ABBVIE INC.	37.85x	8.58x	17.73x	2.35%	519B
ROCHE HOLDING AG	21.6x	5.24x	13.12x	2.49%	388B
MERCK & CO., INC.	105.09x	5.99x	25.53x	2.29%	365B
NOVARTIS AG	23.85x	5.92x	14.34x	2.69%	307B
ASTRAZENECA PLC	24.15x	4.85x	13.63x	1.8%	287B
AMGEN INC.	24x	7.37x	13.6x	2.17%	252B
GILEAD SCIENCES, INC.	-40.15x	7.43x	46.76x	1.93%	212B
Average	31.04x	7.38x	21.58x	2.01%	476B
Weighted average by Cap.	37.23x	8.89x	22.59x	1.68%